Collaboration and License Agreement - Additional Information (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended
	Nov. 30, 2017	Mar. 31, 2021	Mar. 31, 2020	Jan. 01, 2021	Dec. 31, 2020	Jan. 01, 2020
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration agreement revenue recognized		$ 29,305	$ 588
Novartis
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration Revenue	$ 26,900
Novartis | Collaborative Arrangement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration agreement revenue recognized		28,500	$ 600
Deferred revenue		2,000		$ 28,200	$ 30,200	$ 200
Novartis | Collaborative Arrangement | Reimbursable Research and Development Costs
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Accounts receivable		$ 300			$ 400